Nektar Therapeutics Insider Jonathan Zalevsky Sells Shares

Nektar Therapeutics (NASDAQ:NKTR) insider Jonathan Zalevsky sold 10,300 shares of the company's stock on February 19th. The shares were sold at an average price of $1.01 each, amounting to a total value of $10,403.00. This transaction decreased Zalevsky's ownership in the company by 3.15%, leaving him with 316,604 shares, which are valued at approximately $319,770.04. Details of this sale were provided in a legal filing with the SEC, which is publicly accessible.

In addition to this recent transaction, Jonathan Zalevsky sold 51,115 shares on December 19th for an average price of $0.94, totaling $48,048.10.

Nektar Therapeutics Stock Activity

During midday trading, Nektar Therapeutics shares traded down $0.02 to $0.93, with a trading volume of 1,217,794 shares, which is lower than the average volume of 2,430,165 shares. The company's 50-day simple moving average stands at $0.92, while the 200-day average is $1.12. Nektar Therapeutics has a market capitalization of around $171.95 million, and analysts report a P/E ratio of -1.11, with a beta of 0.58. Over the past year, the stock has reached a low of $0.63 and a high of $1.93.

Recent Analyst Ratings

Several analysts have recently commented on Nektar Therapeutics. Piper Sandler initiated coverage with an "overweight" rating and set a target price of $7.00. HC Wainwright maintained a "buy" rating with a target price of $6.50. B. Riley also began coverage with a "buy" rating and a target price of $4.00. In total, two analysts have assigned a hold rating to the stock, while four analysts have rated it as a buy, and one as a strong buy. According to data from MarketBeat.com, the average rating for Nektar Therapeutics is "Moderate Buy", with a consensus price target set at $4.08.

Institutional Investor Activity

Hedge funds and institutional investors have made adjustments to their holdings in Nektar Therapeutics. Two Sigma Securities LLC increased its stake by 56.3% in the fourth quarter, acquiring 27,654 shares after purchasing an additional 9,958 shares. Similarly, Harvest Investment Services LLC and US Asset Management LLC made new positions valued at about $27,000 and $31,000, respectively. Hedge funds and institutional investors currently hold approximately 75.88% of the company's stock.

About Nektar Therapeutics

Nektar Therapeutics is a biopharmaceutical company committed to discovering and developing immunotherapy treatments both in the United States and internationally. The company's primary development focuses include rezpegaldesleukin, a Treg stimulant in phase 2 trials for systemic lupus erythematosus and ulcerative colitis, as well as NKTR-255, which is in phase 1 trials aimed at enhancing the immune system's ability to combat cancer.

For those considering investment in Nektar Therapeutics, recent analyst trends suggest a cautious approach, given the current analyst ratings and recent insider sales.

Nektar, Therapeutics, Insider, Sales, Stocks